Press Releases Johnson & Johnson Santiago S.E.

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 07:01:39 2024-07-17 am EDT			5-day change	1st Jan Change
150.9 ^USD	+1.76%		0.00%	-6.76%

12:49pm	Johnson & Johnson Q2 Adjusted Earnings, Revenue Rise; Lowers Full-Year Earnings Guidance	MT
12:23pm	Earnings Flash (JNJ) JOHNSON & JOHNSON Posts Q2 Revenue $22.45B	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson : 2024 Second-Quarter Press Release & Supplemental Schedules	06:30am	PU
Johnson & Johnson : Second Quarter 2024 2Q24 Other Financial Disclosures	06:30am	PU
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024	06:26am	BU
Johnson & Johnson reports Q2 2024 results	06:21am	BU
Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics	Jul. 12	AQ
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26	Jul. 11	BU
Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)	Jul. 10	AQ
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	Jul. 03	AQ
State AG Updates: June 6-13, 2024	Jul. 02	AQ
CHMP adopts positive opinion for BALVERSA for the treatment of adult patients	Jul. 01	AQ
Johnson & Johnson - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class	Jul. 01	AQ
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	Jun. 28	PU
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	Jun. 28	PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	Jun. 28	PU
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	Jun. 27	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	Jun. 27	AQ
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	Jun. 25	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	Jun. 24	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	Jun. 21	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	Jun. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST